Drug Profile

ARGX 119

Alternative Names: ARGX-119

Latest Information Update: 31 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator argenx; Leiden University Medical Center
Developer argenx
Class Antibodies; Monoclonal antibodies
Mechanism of Action MUSK protein agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Amyotrophic lateral sclerosis
Phase I Congenital myasthenic syndromes

Most Recent Events

19 Dec 2025 Argenx plans a phase II trial for Spinal muscular atrophy (In Children, In adolescents) (IV, Infusion) in December 2025 (NCT07287982)
30 Oct 2025 Argenx plans a registrational trial for Congenital myasthenic syndromes (IV) in 2026
30 Jun 2025 Adverse events andefficacy data from a phase-Ib trial in Congenital myasthenic syndromes released by Argenx

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com